SEATTLE (May 10, 2024)—Global brain and vision research nonprofit BrightFocus Foundation and the Helen Keller Foundation for Research and Education have named ophthalmologist José Cunha-Vaz, MD, PhD, the recipient of the 2024 Helen Keller Prize for Vision Research in recognition of his immense contributions to the field.
This year’s award was presented May 7 during a dinner and ceremony at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), the world’s largest gathering of eye and vision scientists. Keller Johnson-Thompson, great-grand niece of Helen Keller, awarded the prize to Dr. Cunha-Vaz.
From left: Preeti Subramanian, PhD; Caleigh Findley, PhD; Meklit Bekele; and Stacy Pagos Haller (all BrightFocus); Robert Morris, MD, Helen Keller Foundation; 2024 Helen Keller Laureate José Cunha-Vaz, MD, PhD; Hendrik P. N. Scholl, MD; Laura Beckwith, Helen Keller Foundation; Keller Johnson-Thompson, Helen Keller Foundation; Nicholas A. Delamere, PhD, co-chair, prize selection committee; Joe G. Hollyfield, PhD, co-chair, prize selection committee; and Diane Bovenkamp, PhD, BrightFocus.
Dr. Cunha-Vaz’s landmark discoveries have influenced generations of scientists and have had a major impact on clinical practice. These include the discovery of the anatomical location of the blood-retinal-barrier, which is now known to prevent noxious chemicals within the blood stream from entering the eye. This discovery was critical to future pharmacologic and physiological research on normal functional processes in the eye and the understanding of diseases now known to be caused directly by breakdown of the blood-retinal-barrier, such as wet macular degeneration and diabetic retinopathy.
Awarded annually, the Keller Prize recognizes excellence as demonstrated by several significant professional research contributions to vision science or for a single research contribution of exceptional importance to vision science and is chosen by an international panel of biomedical physicians and researchers.
Dr. Cunha-Vaz is emeritus professor of ophthalmology at the University of Coimbra, Portugal, and president of the Association for Innovation and Biomedical Research on Light and Image, a not-for-profit clinical research organization. He is also Honorary Editor of Ophthalmic Research, Coordinator of the Diabetic Retinopathy and Retinal Vascular Diseases Section of the European Vision Institute Clinical Research Network (EVICR.net); he became chair and director of the Department of Ophthalmology at the University of Coimbra Hospital in 1972.
“Dr. Cunha-Vaz’s numerous contributions to vision research have laid the foundation for much of what scientists know today about the blood-retinal-barrier, among other areas,” said Stacy Pagos Haller, President and CEO, BrightFocus Foundation. “He exemplifies the importance of pursuing the untried, the unexpected, and the most promising research to discover cures for vision diseases.
“Dr. Jose Cunha-Vaz discovered how blood vessels in the retina of the eye protect us against sight loss, and what happens when they become diseased. His findings now underlie most retinal vascular therapies, such as the treatment of diabetic retinopathy. He is internationally revered for these studies, spanning decades. Dr. Cunha-Vaz began his research career working with two previous Helen Keller Laureates, Dr. Norman Ashton (1998) and Dr. David Maurice (2003), illustrating the powerful influence of vision research collaborators,” said Robert Morris, MD, president of the Helen Keller Foundation for Research and Education.
About BrightFocus Foundation
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Through its flagship research programs — Alzheimer’s Disease Research, National Glaucoma Research, and Macular Degeneration Research — the Foundation has awarded nearly $300 million in groundbreaking research funding over the past 50 years and shares the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
About Helen Keller Foundation for Research and Education
Based on the legacy of Helen Keller, the Helen Keller Foundation for Research and Education strives to prevent blindness and deafness by advancing research and education. The Foundation aspires to be a leader in integrating sight, speech, and hearing research with the greater biomedical research community, creating and coordinating a peer-reviewed, worldwide network of investigators and institutions.
Laura Beckwith
Chief Operating Officer, Helen Keller Foundation for Research and Education
(205) 933-9389 lbeckwith@helenkellerfoundation.org
About BrightFocus Foundation
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Since its inception more than 50 years ago, BrightFocus and its flagship research programs—Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research—has awarded more than $300 million in research grants to scientists around the world, catalyzing thousands of scientific breakthroughs, life-enhancing treatments, and diagnostic tools. We also share the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
Share this post
News
Related Articles and Information
Press Release
2025 Research Portfolios Spotlight Breakthrough Science
BrightFocus is proudly supporting 186 cutting-edge research grants, fueling the global fight against Alzheimer’s disease, macular degeneration, and glaucoma.
Article
2025 Annual Report Now Available
BrightFocus Foundation’s 2025 annual report celebrates groundbreaking research and public awareness.
Article
BrightFocus Foundation Welcomes New Director of Vision Science Programs
Jimmy Liu, PhD, has joined BrightFocus as Director of Vision Science Programs, bringing deep expertise in eye disease research and a passion for advancing the next generation of vision treatments.
Press Release
New Public Service Campaign Encourages Eye Exams to Save Sight
BrightFocus Foundation's new national public service announcements raise awareness of macular degeneration and glaucoma, leading causes of irreversible blindness among people age 50 and older in the U.S.
Article
Standing Together to Protect Progress: BrightFocus Statement on 2026 National Institutes of Health and National Eye Institute Appropriations
The proposed 2026 federal budget released by the Trump administration would deliver crippling cuts to the National Institutes of Health (NIH). These cuts would threaten essential progress in the fight against Alzheimer’s disease, macular degeneration, and glaucoma—diseases of mind and sight impacting 1 in 7 Americans over age 40.
Article
BrightFocus Statement on Senate Passage of the One Big, Beautiful Bill Act
Legislation jeopardizes health care for millions of Americans living with Alzheimer’s, macular degeneration, glaucoma, and other serious conditions.
Your gift today can help drive innovation in Alzheimer's, macular degeneration, and glaucoma research. By donating, you’ll support life-changing research and provide valuable resources for those affected by these devastating diseases. Give now to fuel hope and bring us closer to finding cures.